Why a Fed rate cut in June is not yet a done deal

An interest-rate cut at the Federal Reserve's June meeting, though now widely expected, should not be viewed as decision that has already been made, Fed watchers say. 


 
The Wacky Negative Interest-Rate Experiment Ends With a Thud

A supposed central-bank innovation never gained traction economically but went on for more than a decade anyway. What was gained?

 
Week Ahead for FX, Bonds in Asia-Pacific: Focus Turns to Economic Data

After a week of multiple central-bank decisions around the globe, focus now turns to economic data as investors seek clues as to their next moves. 


 
Walgreens, Carnival, GameStop and More to Watch This Week

The stock market will be closed on Good Friday. Plus, core PCE price index inflation data and earnings from GameStop, Carnival, and Walgreens Boots Alliance. 


 
The $27 Trillion Treasury Market Is Only Getting Bigger

More debt, different buyers and increased regulation pose challenges. 


 
What's Next for Gold? Look to China for Clues

Gold buying in the country has helped fuel a recent surge-and could protect against a downturn. 


 
Singapore Inflation Quickened Unexpectedly in February

Inflation accelerated unexpectedly in Singapore as prices in key categories like food picked up, backing views that any potential monetary easing is still some time away. 


 
An Economy Perpetually in Crisis Is Shredding Pakistan's Middle Class

The country's political and economic turmoil is leaving middle-class people struggling and the poor battling to survive. 


 
ESG Investing Might Never Recover

Outflows from funds focused on environmental, social and corporate-governance concerns show no signs of stopping. It may be that the moniker has run its course. 


 
US-China Decoupling Poses Supply Chain Risks for Drug Companies

A proposed bill in Congress targets Chinese biotech businesses that play an important role in developing drugs.


(END) Dow Jones Newswires

03-25-24 0515ET